Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Generalized myasthenia gravis
Humanistic burden and health-related quality of life
5 evidence topics · 5 sources
Patient-reported burden by MGFA class: MyRealWorld MG baseline, seven countries
“Adult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline results of 841 participants (mean age 47 years, 70% women) are reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I–IV.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health utilities and medical care use compared with the general population
“In MRW ( n = 1859), 58.4% of respondents had moderate-to-severe MG. Average utility values were lower in MRW versus POPUP (0.739 vs. 0.843 for EQ-5D-5L; 0.493 vs. 0.746 for HUI3), and declined with more severe disease (0.872, 0.707, 0.511 EQ-5D-5L utilities and 0.695, 0.443, 0.168 HUI3 utilities for mild, moderate, and severe MG, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Use of medical care was twice as likely in MRW in comparison with POPUP (51.9% vs. 24.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life and support needs in U.S. adults receiving standard of care without advanced biologics
“Patients had received treatment with standard of care (acetylcholinesterase inhibitors, non-steroidal immunosuppressants, corticosteroids, rituximab, immunoglobulins, plasmapheresis) but not advanced biologics (eculizumab, ravulizumab, zilucoplan, efgartigimod, rozanolixizumab, nipocalimab).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 157 eligible patients completed the survey (87.3% female, mean [SD] age 49.5 [14.4] years, mean [SD] time since diagnosis 11.0 [10.9] years). Mean (SD) MG-QoL-15R score was 16.2 (7.2), EQ5D-5L score was 0.6 (0.3), and FACIT-fatigue subscale score was 20.2 (11.3). Overall, 51.6% received additional support/care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with moderate/severe gMG (136/157 [86.6%]) had greater symptom occurence, reduced treatment satisfaction, greater health-related quality of life impairment, and greater support/care needs, compared with patients with mild gMG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Life domains affected in U.S. patients and caregivers
“across 8 life domains (occupation, financial, emotional, physical, sleep, social, planning and autonomy, and safety)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents included 239 patients with gMG (63%, aged 18–49 y; 69%, female) and 81 caregivers (58%, aged 18–49 y; 42% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 5 domains most impacted by gMG were occupational (mean domain score [SD]: 4.0 [1.2]), planning and autonomy (4.0 [1.1]), financial (3.9 [1.2]), physical (3.9 [1.1]), and sleep (3.9 [1.2]) for patients and financial (3.7 [1.2]), sleep (3.7 [1.1]), occupational (3.6 [1.2]), planning and autonomy (3.6 [1.1]), and safety (3.6 [1.1]) for caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible patients were aged ≥ 18 years currently living in the United States with a self-reported physician diagnosis of gMG regardless of antibody status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of psychological symptoms and health-related quality of life
“Sixty-seven publications were included in the SLR. Compared with the general population, patients with MG experienced worse HRQoL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, in general those with more severe symptoms and hospitalization days had worse depression and anxiety, and fatigue and sleep improved with disease remission and/or improvement. Scores were worse for females compared with males and where evaluated, HRQoL scores generally improved following treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote